Drug
Interleukin 7 clinical trials
Also written CYT107 and Interleukin-7.
Keep track of what changes. Save the Interleukin 7 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2013 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 11
Revimmune (7) · Cytheris SA (6) · National Cancer Institute (NCI) (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Washington University School of Medicine (1) · Fred Hutchinson Cancer Center (1) · Centre Leon Berard (1) · Cytheris, Inc. (1)
Often tested with
Tested in the same studies.
Pneumococcal Vaccines (1) · Hepatitis A Vaccines (1) · Hepatitis B Vaccines (1)
Studies
Open first, then newest update. How each study uses Interleukin 7 is read from its arms, and is right about nine times in ten.
Testing it · 25
- Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)RecruitingPhase 2National Cancer Institute (NCI)NCT07308886Written as CYT107
- Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell TransplantActive, not recruitingPhase 1Washington University School of MedicineNCT06523699Written as Recombinant glycosylated human interleukin-7
- Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaCompletedPhase 2National Cancer Institute (NCI)NCT03513952Written as Glycosylated Recombinant Human Interleukin-7
- InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)TerminatedPhase 2RevimmuneNCT04927169Written as Interleukin-7
- InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )TerminatedPhase 2RevimmuneNCT04426201Written as CYT107
- InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL CohortTerminatedPhase 2RevimmuneNCT04407689Written as Interleukin-7
- InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )TerminatedPhase 2RevimmuneNCT04442178Written as CYT107
- InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK CohortTerminatedPhase 2RevimmuneNCT04379076Written as Interleukin-7
- Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis PatientsTerminatedPhase 2RevimmuneNCT03821038Written as CYT107
- A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis PatientsCompletedPhase 2RevimmuneNCT02640807Written as Interleukin-7
- CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate CancerCompletedPhase 2Fred Hutchinson Cancer CenterNCT01881867Written as Glycosylated Recombinant Human Interleukin-7
- Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood TransplantationWithdrawnPhase 1/2M.D. Anderson Cancer CenterNCT03600896Written as CYT107
- Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or NeuroblastomaCompletedPhase 1/2National Cancer Institute (NCI)NCT00923351Written as rhIL-7
- Immune Reconstitution of Immunosuppressed Sepsis PatientsTerminatedPhase 2University Hospital, LimogesNCT02797431Written as Interleukin-7
- Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had ChemotherapyTerminatedPhase 2National Cancer Institute (NCI)NCT01339000Written as Glycosylated Recombinant Human Interleukin-7
- Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)TerminatedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00839436Written as CYT107
- Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer PatientsCompletedPhase 2Centre Leon BerardNCT01368107Written as interleukin 7
- Study on Interleukin-7 (CYT107) in HIV PatientsTerminatedPhase 2Cytheris SANCT01190111Written as Interleukin-7
- Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-respondersTerminatedPhase 2Cytheris SANCT01241643Written as CYT107
- Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)CompletedPhase 1/2Cytheris SANCT01025596Written as Interleukin-7
Codes
What other systems call Interleukin 7 · ClinicalTrials.gg INT008505
- UNII (FDA) 418XB47Y71INTERLEUKIN-7 HUMAN RECOMBINANTConfirmed FDA, Wikidata
- RxNorm 1367202One source FDA
- Wikidata Q2665532Interleukin 7Confirmed FDA, Wikidata
- NCI Thesaurus C77879Glycosylated Recombinant Human Interleukin-7One source FDA
- DrugBank DB11997One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 418XB47Y71 | INTERLEUKIN-7 HUMAN RECOMBINANT | Confirmed FDA, Wikidata |
| RxNorm | 1367202 | — | One source FDA |
| Wikidata | Q2665532 | Interleukin 7 | Confirmed FDA, Wikidata |
| NCI Thesaurus | C77879 | Glycosylated Recombinant Human Interleukin-7 | One source FDA |
| DrugBank | DB11997 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.